FindTrial
Sign In

Analysis of the association between platelet-aggregation and efficacy and safety after Prasugrel and Clopidogrel administration-A combined analysis of phase III studies in Prasugrel

Analysis of the association between platelet-aggregation and efficacy and safety after Prasugrel and Clopidogrel administration-A combined analysis of phase III studies in Prasugrel - Analysis of the association between platelet-aggregation and efficacy and safety after prasugrel and Clopidogrel administration

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050669
Enrollment
2186
Registered
2023-03-31
Start date
2023-03-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with atherothrombotic cerebral infarction or lacunar infarction who are at high risk of recurrent cerebral infarction

Interventions

None listed

Sponsors

Daiichi Sankyo Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Among patients enrolled in J303, 304, 305 studies, patients with atherothrombotic cerebral infarction or lacunar infarction who are at high-risk for recurrent cerebral infarction.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
PRU at 4 weeks after first-dose—

Secondary

MeasureTime frame
Cumulative incidence of ischemic and bleeding events occurring from the start of study treatment to 48 weeks after first-dose PRU at 24 weeks after first-dose—

Countries

Japan

Contacts

Public ContactSatoru Abe

Daiichi Sankyo Co., Ltd. Primary Medical Science Department

hosokawa.jun.vj@daiichisankyo.co.jp03-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026